|Tonix Pharmaceuticals Holding Corp|
509 Madison Avenue
United States - Map
Tonix Pharmaceuticals Holding Corp., a development stage specialty pharmaceutical company, focuses on the identification and development of pharmaceutical products for the disorders of central nervous system. The companys lead product candidate, TNX-102 sublingual tablet, is a dosage formulation of cyclobenzaprine for the treatment of fibromyalgia and post-traumatic stress disorder. It also has a pipeline of various other product candidates, including TNX-201, which is a treatment for certain types of episodic tension-type headache; and TNX-301 that is indicated for the treatment of alcohol abuse and dependence. The company was founded in 2007 and is headquartered in New York, New York.
|Dr. Seth Lederman M.D.,
Co-Founder, Chairman, Chief Exec. Officer and Pres
|Dr. Donald W. Landry M.D., Ph.D.,
Co-Founder, Director and Member of Governance & Nominating Committee
|Dr. Leland Gershell M.D., Ph.D.,
Chief Financial Officer, Principal Accounting Officer and Treasurer
|Dr. Bruce L. Daugherty Ph.D., M.B.A.,
Sr. Director of Drug Devel., Controller and Sec.
|Dr. Donald J. Kellerman Pharm.D.,
Sr. VP of Clinical Devel. and Regulatory Affairs
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|